Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Acromegaly

• A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
• Vitamin D Metabolism in Patients With Endocrine Disorders
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
• The TMS Treatment for Postoperative Headache in GH Tumor
• A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
• A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
• A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
• A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
• Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
• Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
• Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
• A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
• Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
• Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
• Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
• Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
• Strict IGF-1 Control in Acromegaly
• Cardiac (CMRI) Assessment of Acromegaly
• Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
• Pasireotide LAR and Pegvisomant Study in Acromegaly
• Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
• Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
• Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
• Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
• Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
• Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
• Clomiphene Citrate for Treatment of Acromegaly
• Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
• The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
• Phase II Study With ITF2984 in Acromegalic Patients
• Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
• Predictive Factors Study
• An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
• A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
• Somatuline Predictive Factors in Acromegaly and NET
• A Prospective Study of Outcome After Therapy for Acromegaly
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
• Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
• Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
• Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
• Acromegaly Combination Treatment Study
• Effects of Sandostatin LAR® in Acromegaly
• Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
• Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
• Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
• Tissue Biomarker for Pegvisomant Action
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
• Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S
• Peripheral Metabolic Effects of Somatostatin
• Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
• Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
• Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
• Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
• Open Label Study of Octreotide Implant in Patients With Acromegaly
• Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
• Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
• Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
• Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
• Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
• Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
• Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
• Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
• Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
• Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
• Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
• Prediction of Tumor Shrinkage in Acromegaly
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
• Acute Application of Pegvisomant and Octreotide in Acromegaly
• Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
• Ultrasound Guided Octreotide LAR Injection in Acromegaly
• Physiopathology of Sodium Retention in Acromegaly
• Preoperative Octreotide Treatment of Acromegaly
• Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
• Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
• Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
• Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
• Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
• Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
• Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
• Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
• Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
• Estrogen Treatment in Acromegalic Women
• Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
• Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
• Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
• Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
• Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
• Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
• Octreotide Efficacy and Safety in First-line Acromegalic Patients
• An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
• Canadian Pegvisomant Compassionate Study In Acromegalic Patients
• Somatuline Autogel: Acromegaly Self/Partner Injection Study
• Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
• Long Term Study With B2036-PEG
• Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
• Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
• A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
• Pegvisomant And Sandostatin LAR Combination Study
• A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
• Sandostatin LAR Depot vs. Surgery for Treating Acromegaly